Navigation Links
PARP inhibitor shows activity in pancreatic, prostate cancers among patients carrying BRCA mutations
Date:5/15/2013

PHILADELPHIA In the largest clinical trial to date to examine the efficacy of PARP inhibitor therapy in BRCA 1/2 carriers with diseases other than breast and ovarian cancer, the oral drug olaparib was found to be effective against advanced pancreatic and prostate cancers. Results of the study, led by researchers from the Perelman School of Medicine at the University of Pennsylvania and Sheba Medical Center in Tel Hashomer, Israel, will be presented during the American Society of Clinical Oncology's annual meeting in Chicago in early June (Abstract #11024).

The multi-center research team, including investigators from across the United States, Europe, Australia and Israel, studied nearly 300 patients with inherited BRCA1 and BRCA2 mutations who had advanced cancers that were still growing despite standard treatments. Study participants, comprised of patients with breast, ovarian, pancreatic, prostate and other cancers, all took olaparib.

"Our results show that the BRCA1 or BRCA2 genes inherited by some patients can actually be the Achilles heel in a novel, personalized approach to treat any type of cancer the patient has," says the study's senior author, Susan Domchek, MD, director of Penn's Basser Research Center for BRCA, the nation's only center devoted solely to research for prevention and treatment associated with BRCA mutations. "As many as 3 percent of patients with pancreatic and prostate cancer have an inherited mutation in BRCA1 or BRCA2. Our findings have implications for many patients beyond those with breast and ovarian cancer."

Five of 23 pancreatic cancer patients (22 percent) and four of eight prostate cancer patients (50 percent) responded to the therapy, as measured by objective clinical criteria. Importantly, the therapy also appeared to halt disease progression even in those whose tumors did not shrink: an additional eight (35 percent) of the pancreatic cancer patients studied had stable disease at 8 weeks after beginning olaparib, as did two (25 percent) of the prostate patients. Overall survival at one year was 41 percent for the pancreatic cancer patients, and 50 percent for the prostate cancer patients.

For patients with breast and ovarian cancer, the study confirmed the previously reported activity of olaparib, although tumors treated in this study were much more advanced than in prior studies. For example, in 193 patients with ovarian cancer in whom cisplatin was no longer effective for controlling advanced disease, 31 percent had partial or complete tumor regression on olaparib, and 64 percent were alive at one year. Among 62 patients with metastatic breast cancer patients who had already received at least three chemotherapy regimens, 13 percent responded to new therapy and 45 percent of patients were alive at one year.

The authors found that treatment with olaparib is very well-tolerated. The most commonly reported side effects were mild to moderate fatigue and nausea (each experienced by 59 percent of patients), and transient episodes of vomiting (37 percent). Seventeen percent of patients experienced anemia, and four percent of patients suffered side effects that led to discontinuation of therapy.

As of January 2013, 33 patients remained on the study.

"This study underscores a new paradigm in cancer therapy. We can better fashion treatments for our patients based on a personalized assessment of the genetic factors underlying the cancer," Domchek says. "PARP inhibitors such as olaparib represent the most promising new treatment for individuals suffering from cancer based on inherited BRCA1 and BRCA2 gene mutations."

The results will be presented by lead author Bella Kaufman, MD, from Sheba Medical Center in Tel Hashomer, Israel, in the Tumor Biology poster session from 8 a.m. to noon on Monday, June 3, 2013 in S102 McCormick Place.


'/>"/>

Contact: Holly Auer
holly.auer@uphs.upenn.edu
215-200-2313
University of Pennsylvania School of Medicine
Source:Eurekalert

Related biology news :

1. Blocking DNA: HDAC inhibitor targets triple negative breast cancer
2. Study identifies pathway to enhance usefulness of EGFR inhibitors in lung cancer treatment
3. New inhibitors of elusive enzymes promise to be valuable scientific tools
4. Team solves birth and migration mysteries of cortexs powerful inhibitors, chandelier cells
5. MDC and FMP researchers identify edema inhibitor
6. Genetic survey of endangered Antarctic blue whales shows surprising diversity
7. University of Houston study shows BP oil spill hurt marshes, but recovery possible
8. Weakness can be an advantage in surviving deadly parasites, a new study shows
9. Study shows unified process of evolution in bacteria and sexual eukaryotes
10. Sexual reproduction brings long-term benefits, study shows
11. UCSB study shows forest insects and diseases arrive in US via imported plants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... patient care by providing unparalleled technology to leaders of the medical imaging industry.  As ... added to the range of products distributed by Ampronix. Photo - ... ... ... ...
(Date:5/3/2016)... VILNIUS, Lithuania , May 3, 2016 /PRNewswire/ ... today released the MegaMatcher Automated Biometric Identification ... deployment of large-scale multi-biometric projects. MegaMatcher ABIS can ... and accuracy using any combination of fingerprint, face ... of MegaMatcher SDK and MegaMatcher ...
(Date:4/19/2016)... 2016 The new GEZE SecuLogic ... web-based "all-in-one" system solution for all door components. It ... the door interface with integration authorization management system, and ... The minimal dimensions of the access control and the ... installations offer considerable freedom of design with regard to ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... June 27, 2016  Liquid Biotech ... funding of a Sponsored Research Agreement with The ... cells (CTCs) from cancer patients.  The funding will ... levels correlate with clinical outcomes in cancer patients ... will then be employed to support the design ...
(Date:6/24/2016)... on a range of subjects including policies, debt and investment ... Speaking at a lecture to the Canadian Economics ... the country,s inflation target, which is set by both the ... "In certain areas there needs to be frequent ... not sit down and address strategy together?" He ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers ... 5000 and the 6000i models are higher end machines that use the more unconventional ... spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci has ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in clinical ... Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits ... tips, tools, and strategies for clinical researchers. , “The landscape of how patients ...
Breaking Biology Technology: